Review of 152 patients with bacteremias treated with amikacin.
The efficacy of amikacin treatment of 152 patients with bacteremia was reviewed from case reports submitted by 53 investigators. Eighty-one per cent of these patients had a favorable outcome; 73% were cured and 8% partially cured. Analysis of the 29 treatment failures revealed that the majority (21) were in patients with either pneumonia, leukemia or mixed aerobic-anaerobic infections. Forty-five patients were infected with gentamicin-resistant organisms; 66% of these patients were cured following amikacin therapy, and 14% had a partial cure. These results indicate that amikacin is effective in the therapy of gram-negative bacteremia, even in  seriously ill patients with gentamicin-resistant pathogens.
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D008875:Middle Aged; D018805:Sepsis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology
D005839:Gentamicins; D007612:Kanamycin; D000583:Amikacin